INmune Bio Inc (INMB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $32.51M
Last updated: Nov 17, 2026 at 11:05 AM ET
INmune Bio Inc (INMB) Stock Forecast
Analysts expect INmune Bio (INMB) to earn -$0.58 per share in the fiscal year ending Dec 31, 2026. Of 3 analysts, 3 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 1.67, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 33.3% |
| Buy | 2 | 66.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$0.58
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.43
- EPS consensus, revenue $9.54M
- Next report
- Mar 29, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.58 | -$0.58 to -$0.58 | 1 | N/A | N/A | 3 |
| Dec 31, 2027 | -$0.43 | -$0.43 to -$0.43 | 1 | $9.54M | $3.90M to $15.18M | 2 |
Quarterly Estimates
The EPS consensus rises from -$0.20 for the quarter ending Dec 31, 2026 to -$0.18 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.20 | -$0.23 to -$0.15 | 6 |
| Mar 31, 2027 | -$0.18 | -$0.18 to -$0.18 | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.43.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.58 | -$0.55 | -$0.55 | -$0.55 | -$0.43 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.43 | -$0.49 | -$0.49 | -$0.53 | -$0.53 | N/A |
| Quarter ending Mar 31, 2027 | -$0.18 | -$0.12 | -$0.12 | -$0.12 | -$0.12 | N/A |
Frequently Asked Questions About INMB
What is the INMB stock forecast?
Consensus analyst estimates put INmune Bio's EPS at -$0.58 for the fiscal year ending Dec 31, 2026. The consensus rating from 3 analysts is Buy.
How do analysts rate INMB stock?
Of 3 analysts covering INmune Bio, 1 rates it Strong Buy, 2 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from INMB next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.58, with estimates from -$0.58 to -$0.58 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.43, with estimates from -$0.43 to -$0.43 from 1 analyst.
What revenue do analysts expect from INmune Bio next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $9.54M, with estimates from $3.90M to $15.18M.
How many analysts cover INMB?
3 analysts rate INmune Bio stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
INMB pages: Overview, Earnings, Forecast, Financials, Competitors